US Patent No: 5,869,519

Number of patents in Portfolio can not be more than 2000

C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

This invention is directed to novel (N-substituted)indole ICE-inhibitor compounds. The invention is also directed to pharmaceutical compositions of such indole compounds, plus the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
CONATUS PHARMACEUTICALS, INC.SAN DIEGO, CA23

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bai, Xu Carlsbad, CA 14 85
Karanewsky, Donald S Escondido, CA 122 905

Cited Art

Patent Info (Count) # Cites Year
 
CEPHALON, INC. (1)
5,498,616 Cysteine protease and serine protease inhibitors 46 1994
 
GEORGIA TECH RESEARCH CORPORATION (1)
5,514,694 Peptidyl ketoamides 36 1993
 
PROTOTEK, INC. (1)
5,486,623 Cysteine protease inhibitors containing heterocyclic leaving groups 50 1993

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
CYTOVIA, INC. (9)
6,184,210 Dipeptide apoptosis inhibitors and the use thereof 25 1999
6,153,591 Dipeptide caspase inhibitors and the use thereof 27 1999
6,620,782 Substituted 2-aminobenzamide caspase inhibitors and the use thereof 6 2000
6,355,618 Caspase inhibitors and the use thereof 12 2000
6,495,522 Substituted alpha-hydroxy acid caspase inhibitors and the use thereof 10 2000
6,596,693 Dipeptide apoptosis inhibitors and the thereof 3 2000
6,566,338 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death 7 2000
6,716,818 Caspase inhibitors and the use thereof 7 2001
6,949,516 Dipeptide apoptosis inhibitors and the use thereof 1 2003
 
CONATUS PHARMACEUTICALS, INC. (7)
6,197,750 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases 18 1998
6,544,951 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases 3 2000
6,489,353 C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases 0 2000
7,053,056 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases 0 2001
6,790,989 Inhibitors of the ICE/ced-3 family of cysteine proteases 0 2001
6,610,683 Treatment of infectious disease using interleukin-1.beta.-converting enzyme (ICE)/CED-3 family inhibitors 0 2001
7,183,260 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases 0 2004
 
OSI PHARMACEUTICALS, INC. (6)
6,156,528 Methods for using a phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia 1 1998
6,130,053 Method for selecting compounds for inhibition of neoplastic lesions 8 1999
6,177,471 Method for treating patients with acne by administering a CGMP-specific PDE inhibitor 18 1999
6,500,610 Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds 3 1999
6,555,547 Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative 1 2000
6,569,638 Method for screening compounds for the treatment of neoplasia 0 2000
 
VERTEX PHARMACEUTICALS INCORPORATED (3)
7,417,029 Prodrug of an ice inhibitor 3 2001
7,531,570 Treatment of diseases using ICE inhibitors 0 2005
8,022,041 Prodrug of an ICE inhibitor 0 2008
 
IDUN PHARMACEUTICALS, INC. (1)
6,515,173 Inhibitors of the ICE/ced-3 family of cysteine proteases 1 2000
 
SMITHKLINE BEECHAM CORPORATION (1)
6,787,651 Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-.gamma. binding agents 9 2001
 
VERTEXD PHARMACEUTICALS INCORPORATED (1)
8,329,662 Prodrug of an ICE inhibitor 0 2011
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (1)
8,389,474 Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion 0 2010